FDA Testing Regs Should Be Loosened, Allow More Human Models – Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug sponsors need less expensive options beyond traditional animal models to fulfill preclinical data requirements, coalition of 14 groups and companies says.
You may also be interested in...
"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon
The agency is planning a library of validated computer models of how patients respond to medical treatments.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.